Abstract 562P
Background
Osi is a third-generation, CNS active EGFR-TKI. The primary analysis of the global, phase III, open-label, randomised FLAURA2 (NCT04035486) study in pts with EGFRm advanced NSCLC demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with 1L osi + chemotherapy (osi + CT) vs osi monotherapy (osi-mono). We report data of pts in China from FLAURA2.
Methods
Eligible pts (aged ≥18 yrs with locally advanced/metastatic EGFRm [Ex19del/L858R] NSCLC, WHO PS 0/1 and no prior systemic treatment [tx] for advanced NSCLC; stable CNS metastases allowed) were randomised 1:1 to osi + CT (osi 80 mg QD + pemetrexed [pem] 500 mg/m2 + either cisplatin 75 mg/m2 or carboplatin AUC5 Q3W for 4 cycles, followed by osi 80 mg QD + pem 500 mg/m2 Q3W) or osi-mono (80 mg QD) until progression/discontinuation criterion; stratified by race (Chinese Asian/non-Chinese Asian/non-Asian), EGFR mutation test method (local/central) and WHO PS (0/1). Primary endpoint: PFS by investigator assessment. Secondary endpoints included OS, ORR, DoR and safety. Data cut-off: 03 April 2023.
Results
Overall, 131 pts in China were randomised to osi + CT (n=67) or osi-mono (n=64). Baseline characteristics (osi + CT/osi-mono) were: median age (range), 61 (42–74)/60 (32–78) yrs; 63/59% female; 48/59% Ex19del; 51/39% L858R (1 unknown EGFR mutation type per arm); 51/42% CNS metastases. Osi + CT improved PFS vs osi-mono (49% maturity by investigator; Table). OS was immature (21% maturity); HR 0.97 (95% CI 0.45, 2.06). All grade ≥3 AEs (osi + CT/osi-mono): 75% (mainly haematological)/26%; AEs leading to osi discontinuation: 3/5%.
Conclusions
In the China cohort, osi + CT demonstrated a clinically meaningful improvement in PFS over osi-mono with a manageable safety/tolerability profile consistent with the global study population, supporting osi + platinum-pem as a new 1L tx option for pts in China with advanced EGFRm NSCLC. Table: 562P
Efficacy output | Osi + CT (n=67) | Osi-mono (n=64) |
Median PFS by investigator, months (95% CI) | 27.4 (22.3, NC) | 22.3 (16.7, 25.0) |
HR (95% CI) | 0.56 (0.34, 0.92) | |
Median follow-up for PFS, months (range)* | 22.3 (0–30.6) | 23.7 (3.0–33.1) |
Median PFS by BICR, months (95% CI) | 33.2 (25.1, NC) | 22.0 (16.6, NC) |
HR (95% CI) | 0.58 (0.34, 1.01) | |
Median follow-up for PFS, months (range)* | 24.2 (0–30.5) | 22.3 (3.0–33.2) |
ORR by investigator, n (%) | 58 (87) | 49 (77) |
Median DoR by investigator, months (95% CI) | 26.2 (20.7, NC) | 20.8 (15.3, 23.5) |
∗In censored pts.BICR, blinded independent central review; CI, confidence interval; DoR, duration of response; HR, hazard ratio; NC, not calculable; NR, not reached; ORR, objective response rate
Clinical trial identification
FLAURA2: NCT04035486.
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, Ph.D., of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
L. Jiang: Non-Financial Interests, Personal, Local PI: Shanghai Chest Hospital, Shanghai Jiao Tong University, PR China. J. Liu, Y. Liu: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. D. Kulkarni, X. Huang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. P.A. Jänne: Financial Interests, Personal, Advisory Board: AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyte, Takeda Oncology, Novartis, Voronoi, SFJ Pharmaceuticals, Biocartis, LOXO Oncology, PUMA, Sanofi, Transcenta, Daiichi Sa; Financial Interests, Personal, Other: Dr. Jänne is a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Oncology, PUMA, Astellas Pharmaceuticals, Daiichi Sankyo; Financial Interests, Personal, Royalties: Post marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp. All other authors have declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract